Log in

OTCMKTS:IPATFImmunoprecise Antibodies Stock Price, Forecast & News

$1.12
-0.18 (-13.85 %)
(As of 07/3/2020 08:56 AM ET)
Add
Compare
Today's Range
$1.12
Now: $1.12
$1.30
50-Day Range
$0.58
MA: $1.11
$1.45
52-Week Range
$0.23
Now: $1.12
$1.52
Volume185,641 shs
Average Volume72,776 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, and Europe. It also provides human antibody development, hybridoma development, genetic immunization, rabbit monoclonal antibody development, recombinant protein expression and production, cryostorage, hybridoma sequencing, antibody generation, antibody purification, polyclonal development, and peptide production services. The company has a collaboration agreement with TetraGenetics, Inc. to focus on the discovery of novel human monoclonal antibodies against three undisclosed therapeutically-relevant ion-channels. The company was founded in 1989 and is based in Victoria, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IPATF
CUSIPN/A
CIKN/A
Phone250-483-0308

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive IPATF News and Ratings via Email

Sign-up to receive the latest news and ratings for IPATF and its competitors with MarketBeat's FREE daily newsletter.

Immunoprecise Antibodies (OTCMKTS:IPATF) Frequently Asked Questions

How has Immunoprecise Antibodies' stock been impacted by COVID-19 (Coronavirus)?

Immunoprecise Antibodies' stock was trading at $0.53 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IPATF stock has increased by 111.3% and is now trading at $1.12. View which stocks have been most impacted by Coronavirus.

Has Immunoprecise Antibodies been receiving favorable news coverage?

Press coverage about IPATF stock has been trending negative on Friday, InfoTrie reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Immunoprecise Antibodies earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Immunoprecise Antibodies.

Who are some of Immunoprecise Antibodies' key competitors?

Who are Immunoprecise Antibodies' key executives?

Immunoprecise Antibodies' management team includes the following people:
  • Dr. James S. Kuo M.B.A., M.D., Chairman (Age 54)
  • Dr. Jennifer Bath, Pres, CEO & Director
  • Mr. Robert Beecroft, Founder & Director
  • Mr. Charles Wheelock, Global Chief Technology Officer
  • Ms. Lisa Helbling, Chief Financial Officer

What is Immunoprecise Antibodies' stock symbol?

Immunoprecise Antibodies trades on the OTCMKTS under the ticker symbol "IPATF."

How do I buy shares of Immunoprecise Antibodies?

Shares of IPATF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immunoprecise Antibodies' stock price today?

One share of IPATF stock can currently be purchased for approximately $1.12.

What is Immunoprecise Antibodies' official website?

The official website for Immunoprecise Antibodies is www.immunoprecise.com.

How can I contact Immunoprecise Antibodies?

The company can be reached via phone at 250-483-0308.

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.